Get started
Atrium Therapeutics, Inc.Atrium Therapeutics, Inc.Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc.

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsETFs
Full chart
Full chart

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪218.10 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−49.50 M‬ USD
Revenue (FY)
‪18.62 M‬ USD
Shares float
‪17.07 M‬
Beta (1Y)
1.23

About Atrium Therapeutics, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Kathleen Gallagher
Website
atriumtherapeutics.com
Headquarters
San Diego
Identifiers
3
ISIN US04965N1046
CFI code
ESVUFR
Atrium Therapeutics, Inc. operates as a biopharmaceutical company that provides RNA therapeutics services to the heart to transform the standard of care for people living with cardiomyopathies. Its products pipeline includes two lead development candidates: ATR 1072 for PRKAG2 syndrome and ATR 1086 for PLN cardiomyopathy, both conditions are severe, life-threatening, rare autosomal dominant progressive cardiomyopathies with no approved treatment options and high unmet need. The company was founded on September 30, 2025 and is headquartered in San Diego, CA.

Check out other big names from the same industry as RNA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

ETFs holding the stock


IWO
iShares Russell 2000 Growth Fund
Weight 0.01%
Market value ‪1.24 M‬
JSML
Janus Henderson Small Cap Growth Alpha ETF
Weight 0.29%
Market value ‪999.66 K‬
VBR
Vanguard Small-Cap Value ETF
Weight 0.00%
Market value ‪714.58 K‬
VBK
Vanguard Small-Cap Growth ETF
Weight 0.00%
Market value ‪611.44 K‬
FGLS
Fidelity Global Value Long/Short Fund
Weight 0.05%
Market value ‪510.46 K‬
FESM
Fidelity Enhanced Small Cap Core ETF
Weight 0.00%
Market value ‪139.08 K‬
VTWG
Vanguard Russell 2000 Growth ETF
Weight 0.01%
Market value ‪136.81 K‬
KOMP
State Street SPDR S&P Kensho New Economies Composite ETF
Weight 0.00%
Market value ‪52.20 K‬
SCHK
Schwab 1000 Index ETF
Weight 0.00%
Market value ‪13.87 K‬
XMEM
Xtrackers MSCI Emerging Markets Swap UCITS ETF Capitalisation 1C
Weight 0.00%
Market value ‪10.07 K‬
XMCM
Xtrackers MSCI Emerging Markets Swap UCITS ETF
Weight 0.00%
Market value ‪10.07 K‬

Explore more ETFs 

Frequently asked questions


The current price of RNA is 12.61 USD — it has decreased by −1.10% in the past 24 hours. Watch Atrium Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Atrium Therapeutics, Inc. stocks are traded under the ticker RNA.
RNA stock has risen by 8.71% compared to the previous week, the month change is a −6.45% fall, over the last year Atrium Therapeutics, Inc. has showed a −13.51% decrease.
We've gathered analysts' opinions on Atrium Therapeutics, Inc. future price: according to them, RNA price has a max estimate of 72.00 USD and a min estimate of 25.00 USD. Watch RNA chart and read a more detailed Atrium Therapeutics, Inc. stock forecast: see what analysts think of Atrium Therapeutics, Inc. and suggest that you do with its stocks.
RNA reached its all-time high on Mar 5, 2026 with the price of 16.77 USD, and its all-time low was 11.40 USD and was reached on Jun 11, 2026. View more price dynamics on RNA chart.
See other stocks reaching their highest and lowest prices.
RNA stock is 2.82% volatile and has beta coefficient of 1.23. Track Atrium Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Atrium Therapeutics, Inc. there?
Today Atrium Therapeutics, Inc. has the market capitalization of ‪218.10 M‬, it has increased by 1.08% over the last week.
Yes, you can track Atrium Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Atrium Therapeutics, Inc. is going to release the next earnings report on Sep 2, 2026. Keep track of upcoming events with our Earnings Calendar.
RNA earnings for the last quarter are −0.97 USD per share, whereas the estimation was −1.05 USD resulting in a 7.62% surprise. The estimated earnings for the next quarter are −1.42 USD per share. See more details about Atrium Therapeutics, Inc. earnings.
Atrium Therapeutics, Inc. revenue for the last quarter amounts to ‪19.64 M‬ USD, despite the estimated figure of ‪2.00 M‬ USD. In the next quarter, revenue is expected to reach ‪1.00 M‬ USD.
RNA net income for the last quarter is ‪−16.63 M‬ USD, while the quarter before that showed ‪−29.14 M‬ USD of net income which accounts for 0.00% change. Track more Atrium Therapeutics, Inc. financial stats to get the full picture.
No, RNA doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, RNA shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Atrium Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.